Should new antimalarial drugs be subsidized?

Journal of Health Economics

Volumn 29, Issue 3, 2010, Pages 445-456

  Laxminarayan, Ramanan ^a,b   Parry, Ian W H ^a   Smith, David L ^a,c   Klein, Eili Y ^a,b  

^a RESOURCES FOR THE FUTURE   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antimalarial drugs; Resistance externality; Subsidies; Transmission externality; Welfare effects

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; CHLOROQUINE;

DISEASE RESISTANCE; DISEASE TRANSMISSION; DISEASE TREATMENT; DRUG; DRUG RESISTANCE; MALARIA; SUBSIDY SYSTEM; WELFARE IMPACT;

ANTIBIOTIC RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; CONCEPTUAL FRAMEWORK; DISEASE TRANSMISSION; DRUG COST; ENDEMIC DISEASE; INFECTION RISK; MALARIA; RISK ASSESSMENT; RISK REDUCTION;

ANIMALS; ANTIMALARIALS; CULICIDAE; DRUG COSTS; DRUG RESISTANCE; FINANCING, GOVERNMENT; HUMANS; MALARIA; MODELS, THEORETICAL;

EID: 77952550458     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2010.03.002     Document Type: Article

References (51)

1. Anderson R.M., May R.M. Infectious Diseases of Humans 1991, Oxford University Press, Oxford.
2. Aron J., May R.M. The population dynamics of malaria. Population Dynamics and Infectious Disease 1982, 139-179. Chapman and Hall, London. R.M. Anderson (Ed.).
3. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance 2004, Institute of Medicine, Washington, DC. K.J. Arrow, C.B. Panosian (Eds.).
4. Beier J., Killeen G., et al. Short report: entomologic inoculation rates and Plasmodium falciparum malaria prevalence in Africa. American Journal of Tropical Medicine and Hygiene 1999, 61:109-113.
5. Bonhoeffer S., Lipsitch M., et al. Evaluating treatment protocols to prevent antibiotic resistance. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:12106-12111.
6. Boni M.F., Feldman M.W. Evolution of antibiotic resistance by human and bacterial niche construction. Evolution: International Journal of Organic Evolution 2005, 59:477-491.
7. Branch O., Casapia W.M., et al. Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. Malaria Journal 2005, 4:27.
8. Chima R.I., Goodman C.A., et al. The economic impact of malaria in Africa: a critical review of the evidence. Health Policy 2003, 63:17-36.
9. Cornille-Brogger R., Mathews H.M., et al. Changing patterns in the humoral immune response to malaria before, during, and after the application of control measures: a longitudinal study in the West African Savanna. Bulletin of the World Health Organization 1978, 56:579-600.
10. Dietz K., Molineaux L., et al. A malaria model tested in the African Savannah. Bulletin of the World Health Organization 1974, 50:347-357.
11. Drummond M., O'Brien B., et al. Methods for the Economic Evaluation of Health Care Programmes 1997, Oxford University Press, Oxford. second ed.
12. Goodman C.A., Coleman P.G., et al. Cost-effectiveness of malaria control in sub-Saharan Africa. The Lancet 1999, 354:378-385.
13. Gu W., Mbogo C.M., et al. Low recovery rates stabilize malaria endemicity in areas of low transmission in coastal Kenya. Acta Tropica 2003, 86:71-81.
14. Hastings I.M. A model for the origins and spread of drug-resistant malaria. Parasitology 1997, 115:133-141.
15. Hastings I.M., Donnelly M.J. The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resistance Updates 2005, 8:43-50.
16. Hay S.I., Guerra C.A., et al. Urbanization, malaria transmission and disease burden in Africa. Nature Reviews Microbiology 2005, 3:81-90.
17. Hayward R., Saliba K.J., et al. pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum. Molecular Microbiology 2005, 55:1285-1295.
18. Hien T.T., White N.J., et al. Qinghaosu. The Lancet 1993, 341:603-608.
19. Jambou R., Legrand E., et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-Type PfATPase6. The Lancet 2005, 366:1960-1963.
20. Kidgell C., Volkman S.K., et al. A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathogens 2006, 2:e57.
21. Koella J.C. On the use of mathematical models of malaria transmission. Acta Tropica 1991, 49:1-25.
22. Koella J.C., Antia R. Epidemiological models for the spread of anti-malarial resistance. Malaria Journal 2003, 2:3.
23. Koella J.C. Costs and benefits of resistance against antimalarial drugs. Parasitology Today 1998, 14:360-364.
24. Laxminarayan R. ACT now or later? Economics of malaria resistance. American Journal of Tropical Medicine and Hygiene 2004, 71:187-195.
25. Mbogo C.M., Mwangangi J.M., et al. Spatial and temporal heterogeneity of anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast. American Journal of Tropical Medicine and Hygiene 2003, 68:734-742.
26. Médecins Sans Frontières Act Now to Get Malaria Treatment That Works to Africa 2003, Médecins Sans Frontières, Geneva.
27. Mendis C., Jacobsen J.L., et al. Anopheles arabiensis and An. funestus are equally important vectors of malaria in Matola Coastal suburb of Maputo, Southern Mozambique. Medical and Veterinary Entomology 2000, 14:171-180.
28. Miller T.R. Variations between Countries in values of statistical life. Journal of Transport Economics and Policy 2000, 34:169-188.
29. Morel C.M., Lauer J.A., et al. Cost effectiveness analysis of strategies to combat malaria in developing countries. British Medical Journal 2005, 331:1299-1306.
30. Philipson T.J., Mechoulan S. Intellectual Property and External Consumption Effects: Generalizations from Health Care Markets. Working Paper 9598 2003, National Bureau of Economic Research, Cambridge, MA.
31. Pringle G., Avery-Jones S. Observations on the early course of untreated falciparum malaria in semi-immune African children following a short period of protection. Bulletin of the World Health Organization 1966, 34:269-272.
32. Roll Back Malaria, World Health Organization, UNICEF World Malaria Report 2005 2005, WHO, Geneva.
33. Rudholm N. Economic implications of antibiotic resistance in a global economy. Journal of Health Economics 2002, 21:1071-1083.
34. Sama W., Killeen G., et al. Estimating the duration of Plasmodium falciparum infection from trials of indoor residual spraying. American Journal of Tropical Medicine and Hygiene 2004, 70:625-634.
35. Smith D.L., McKenzie F.E. Statics and dynamics of malaria infection in Anopheles mosquitoes. Malaria Journal 2004, 3:13.
36. Smith D.L., Dushoff J., et al. The entomological inoculation rate and Plasmodium falciparum infection in African children. Nature 2005, 438:492-495.
37. Snow R.W., Marsh K. The consequences of reducing transmission of Plasmodium falciparum in Africa. Advances in Parasitology 2002, 52:235-264.
38. Snow R.W., Guerra C.A., et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434:214-217.
39. Trape J.F. The public health impact of chloroquine resistance in Africa. American Journal of Tropical Medicine and Hygiene 2001, 64:12-17.
40. Trape J.F., Pison G., et al. Impact of chloroquine resistance on malaria mortality. Comptes Rendus de l'Académie des Sciences. Série III, Sciences de la vie 1998, 321:689-697.
41. United Nations Statistics Division, 2006. Common Database. Accessed 31.05.2006, available at http://unstats.un.org/.
42. Varian H.R. Microeconomic Analysis 1984, Norton, New York.
43. Wang S.J., Lengeler C., et al. Rapid urban malaria appraisal (Ruma) III: epidemiology of urban malaria in the municipality of Yopougon (Abidjan). Malaria Journal 2006, 5:28.
44. White N.J. Preventing antimalarial drug resistance through combinations. Drug Resistance Updates 1998, 1:3-9.
45. White N.J. Antimalarial drug resistance and combination chemotherapy. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences 1999, 354:739-749.
46. White N.J. Antimalarial drug resistance. Journal of Clinical Investigation 2004, 113:1084-1092.
47. White N.J., Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proceedings Biological Sciences 2003, 270:545-554.
48. WHO Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation 2001, World Health Organization, Geneva.
49. WHO Improving the Affordability and Financing of Artemisinin-Based Combination Therapies 2003, World Health Organization, Geneva.
50. WHO World Malaria Report 2008 2008, World Health Organization, Geneva.
51. Wootton J.C., Feng X., et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002, 48:320-323.